Mayne Pharma Group Ltd. · ASX:MYX
Mayne Pharma — FY2026 Earnings Presentation
35 slides from Mayne Pharma's earnings presentation, Aug 27, 2026
Slide 1: FY26 Results Presentation
For personal use only Mayne Pharma Group Limited FY26 Results Presentation Aaron Gray (CEO) Griffin Buchanan (CFO) 27 August 2026
Slide 2: Disclaimer
Disclaimer The information provided is general in nature and is in summary form only. It is not complete and should be read in conjunction with the company’s audited Financial Statements and market For personal use only disclosures. This material is not intended to be relied upon as advice to invest
Slide 3: FY26 Corporate Highlights
FY26 Corporate Highlights A year of resilience and focus against a backdrop of general operational distraction and disruption For personal use only Realignment of Women’s Health Sales Force • Refreshed sales and marketing materials • Dedicated menopause and contraception field representation driving
Slide 4: Global Headcount & Sales Force
Global Headcount & Sales Force Global footprint T O TA L H E A D C O U N T 1 470 Employees For personal use only United States Current Women’s Health sales representation of ~90 persons 227 82% Employees FY26 sales mix Lexington, KY | Raleigh, NC Current DistributeRx sales representation of ~23 pers
Slide 5: FY26 Financial Highlights
FY26 Financial Highlights1 Margin expansion and resilient segment contribution through a year of disruption and reinvestment For personal use only $383.7m 64.7% $34.2m Revenue Gross margin Underlying EBITDA2 down 6% FY25 Up 4.1% from 60.6% FY25 down 27% from $47.0m FY25 $107.1m $34.5m $80.0m Total d
Slide 6: FY26 Group Financial Performance
For personal use only FY26 Group Financial Performance
Slide 7: Group Continuing Operations Overview: Summary
Group Continuing Operations Overview: Summary Change vs Change vs A$ million1 FY26 FY25 FY25 ($) FY25 (%) Reported Revenue 383.7 408.1 (24.4) -6% For personal use only Reported Gross Profit 248.1 247.3 0.8 0% Reported Direct Contribution 107.1 109.7 (2.6) -2% Reported EBITDA 141.4 18.4 123.0 668% Un
Slide 8: Group Continuing Operations Overview: EBITDA Reconciliation
Group Continuing Operations Overview: EBITDA Reconciliation Change vs Change vs For personal use only A$ million FY26 FY25 FY25 ($) FY25 (%) Reported EBITDA 141.4 18.4 123.0 668% Scheme legal fees (inc. litigation) 11.8 8.5 3.3 39% Earn-out Reassessments (125.6) 16.6 (142.2) -857% Fair Value Adjustm
Slide 9: Group Cash + Marketable Securities balance ($m)
Group Cash + Marketable Securities balance ($m) 34.5 -12.6 For personal use only -12.5 -10.3 -8.1 -2.9 -3.2 -2.9 -2.3 100.4 99.5 88.4 80.0 30 Jun 2025 30 Jun 2026 Cash balance Cash balance Continuing operations1 Discontinued operations Investing & Financing (5% net cash used) (46% net cash used) (48
Slide 10: Segment Performance
For personal use only Segment Performance
Slide 11: FY26 Snapshot – Segments
FY26 Snapshot – Segments For personal use only FY26 Revenue Contribution FY26 Segment Contribution FY26 Total Direct Contribution (A$m, % of total) (A$m, % of total) A$4.6, 4% A$70.7, 18% A$44.5, 42% $107.1m A$138.7, 36% A$174.3, 46% A$57.9, 54% Women’s Health Dermatology/DistributeRx International
Slide 12: FY26 Segment Operating Highlights
FY26 Segment Operating Highlights Women’s Health Dermatology International For personal use only • Launch of TWYNEO® and EPSOLAY® • Inaugurated the $18m Salisbury facility • FDA removal of “Black Box” warning for HRTs1 in upgrade, recognised in export and business management of menopause: BIJUVA® re
Slide 13: FY26 Segment Financial Highlights
FY26 Segment Financial Highlights Women’s Health Dermatology International For personal use only • Revenue $US118.2m (+2% pcp) | $174.3m (-2% pcp) • Revenue US$94.1m(-6% pcp) | $138.7m (-10% pcp) • Revenue $70.7 million (-7% versus pcp) o NEXTSTELLIS®: +15% Demand Cycles1, +6% US$45.2m o BIJUVA®: +2
Slide 14: Women's Health
For personal use only Women’s Health
Slide 15: The Rise of Menopause
The Rise of Menopause Global footprint Key Drivers FY26 Penetration of Category1: ~1% For personal use only 90 84 Total Prescriptions (TRx, ‘000) 77 80 67 • Regulatory de-risking of the category: FDA announced black boxed-warning 70 61 removal for certain hormone replacement therapies (HRTs) in Nov
Slide 16: Contraception
Contraception Global footprint FY26 Penetration of Category1: ~3% Key Drivers Demand cycles (‘000) and Sequential Growth (%) Net Sales (US$m) & Growth (%) For personal use only 28.0 63% 4% 10.6% 9% 194 23.4 200.0 8.4% 1.8% 2.9% -0.6% 100.0% 22.4 23% 21.8 176 175 23.0 20.1 • Affordable Care Act benef
Slide 17: Dermatology and DistributeRx
For personal use only Dermatology and DistributeRx
Slide 18: Dermatology portfolio mix shift drives margins & contribution growth
Dermatology portfolio mix shift drives margins & contribution growth FY25 Revenue by Category – TOTAL $154.1 million FY26 Revenue by Category – TOTAL $138.7 million For personal use only Total Revenue Growth: -10% $80.6, 58% $83.1, 54% $71.0, 46% Gross Margin Growth +1018 bps $58.1, 42% Gross Profit
Slide 19: Dermatology Products
Dermatology Products Global footprint A portfolio of branded and generics Branded Portfolio For personal use only Last Patent Expiry Dermatology 2030 6 Branded Products 2034 20351 25 Generics, Authorised Generics Products 2039 31 Total Mayne Pharma Dermatology Products 2041 2041 19 1. RHOFADE® gener
Slide 20: Mayne Pharma Disintermediation
Mayne Pharma Disintermediation Disintermediation: For personal use only Involves removing the intermediaries (wholesalers or others) between the manufacturer (Mayne Pharma) and the patient DistributeRx is Mayne Pharma's direct-to-patient distribution platform with Adelaide Apothecary serving as Mayn
Slide 21: Prescription Access Made Simple
PRESCRIPTION ACCESS MADE SIMPLE For personal use only DistributeRx partners with manufacturers, providers, and pharmacies to improve patient access and offer predictable prices • ePharmacy size ~US$252 billion by 2030 (CAGR 17%)1 driven by rising consumer adoption of digital pharmacy and home delive
Slide 22: DistributeRx product portfolio
Global footprint 100% Mayne Pharma owned subsidiary with a portfolio of branded and generics, both Mayne Pharma owned and Via Third Parties For personal use only 31 Mayne Pharma Dermatology Products1 + 208 Other Non-Mayne Products sold via DistributeRx Channel1 239 Total Products 14 Additional Pipel
Slide 23: International
For personal use only International
Slide 24: NEXTSTELLIS® in Australia
NEXTSTELLIS® in Australia Australian Demand cycles (‘000) 55.00 49 45.00 For personal use only • Officially added to the Pharmaceutical Benefits Scheme 34 35.00 (PBS) on 1 October 2025 (Q2 FY26) PBS approval 27 1 Oct • Australian women now have better access to affordable 25.00 17 contraceptive opti
Slide 25: Future Growth Drivers
Future Growth Drivers Women’s Health Dermatology International For personal use only • Drive market penetration – increase low single digit • Scale disintermediation – specialty pharmacy • Salisbury capacity – post-upgrade enabling higher market share + solid market growth ecosystem to reduce fricti
Slide 26: FY27 focus and outlook
FY27 focus and outlook For personal use only • Women’s Health: accelerate portfolio growth through a focused salesforce, refreshed marketing and improved prescriber access, underpinned by the macro tailwind from the removal of the HRT Black Box warning of the menopause category, in particular for BI
Slide 27: Q&A
Q&A For personal use only For further information contact: Dr Tom Duthy Investor Relations +61 402 493 727 ir@maynepharma.com Click here to view this Presentation on Investor Hub This presentation has been approved for release by the Board of Directors of Mayne Pharma You deserve tomorrow. 27
Slide 28: Appendix
For personal use only Appendix
Slide 29: Snapshot
Snapshot Corporate Summary1,2 • Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more For personal use only accessible medicines Share price (ASX:MYX) $3.26 GICS Industry Group Code (Pharmaceuticals) 3
Slide 30: Segment Performance
Segment Performance For personal use only Change vs Change vs Reported results (A$million) 1HFY26 2HFY26 FY25 FY26 FY25 1HFY26 2HFY26 FY25 FY26 FY25 1 Revenue Gross profit Women's Health 96.5 77.8 178.4 174.3 -2% Women's Health 76.2 61.8 142.9 138.0 -3% Dermatology 78.6 60.1 154.1 138.7 -10% Dermato
Slide 31: Women's Health: portfolio performance (USD and AUD)
Women’s Health: portfolio performance (USD and AUD) Women's Health in US$'000 1HFY26 2HFY26 FY25 FY26 Total Revenue 63,246 54,961 115,510 118,207 For personal use only Total Gross Profit 49,946 43,690 92,545 93,636 Total Gross Profit % of Revenue 79% 0% 80% 79% Direct OPEX (26,198) (28,154) (52,389)
Slide 32: Dermatology: Improvements in product mix delivers strong contribution
Dermatology: Improvements in product mix delivers strong contribution (USD & AUD) Dermatology in US$'000 1HFY26 2HFY26 FY25 FY26 For personal use only Total Revenue 51,510 42,569 99,786 94,079 Total Gross Profit 33,468 26,689 53,645 60,157 Total Gross Profit % of Revenue 65% -1% 54% 64% Direct OPEX
Slide 33: International: strategic and operational levers building momentum
International: strategic and operational levers building momentum (AUD) For personal use only International in A$'000 1HFY26 2HFY26 FY25 FY26 Reported Revenue 36,923 33,785 75,643 70,708 Reported Gross Profit 11,268 10,067 21,533 21,335 Total Gross Profit % of Revenue 31% 0% 28% 30% Direct OPEX (9,2
Slide 34: Reported EBITDA to Underlying Bridge
Reported EBITDA to Underlying Bridge A$million 1HFY26 2HFY26 FY25 FY26 Reported Revenue 212.1 171.6 408.1 383.7 Reported Gross Profit 138.6 109.5 247.3 248.1 For personal use only Total Gross Profit % of Revenue 65% -1% 61% 65% Direct OPEX (70.5) (70.5) (137.6) (141.0) Direct Contribution* 68.1 39.0
Slide 35: Consolidated Balance Sheet
Consolidated Balance Sheet 30-Jun-25 30-Jun-26 Change For personal use only Balance Sheet Extract A$m A$m A$m Cash 59.8 80.0 20.2 Marketable securities 40.6 - (40.6) Receivables 180.6 174.6 (6.0) Inventory 50.6 55.5 4.9 Income tax receivable 1.3 1.0 (0.3) PP&E 53.1 51.3 (1.8) Intangible assets inclu